Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Msci Inc (MSCI) vs Twist Bioscience Corp (TWST) Price & Performance

Msci IncTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Msci Inc vs Twist Bioscience Corp — how do they compare? Msci Inc trades at $562.92 (market cap $45.51B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Msci Inc is far larger — about 8.4× Twist Bioscience Corp's market cap, and Msci Inc pays a 1.31% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

MSCITWST
Market Cap
$45.51B$5.45B
Sector
FinancialsHealth
52-Week High
$643.83$102.88
52-Week Low
$511.84$24.16
Enterprise Value
$51.67B$5.37B
Dividend Yield
1.31%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Msci Inc

MSCI is trading at $561.74, down 10.64% today, but maintains strong fundamentals with consistent earnings beats and robust profitability. The company reported Q2 2026 EPS of $4.94, exceeding estimates of $4.90, driven by recurring subscription growth and ETF-linked AUM. Technical indicators show a bullish trend with key support at $606, while valuation ratios remain elevated with a P/E of 35.7. Recent strategic partnerships with UBS and the acquisition of First Street enhance its private markets and climate risk capabilities.

Outlook remains positive with 73% analyst buy ratings and a $725.44 consensus price target, implying 29% upside. Risks include high debt levels ($4.51B) and competitive pressures in financial data services. The stock offers growth potential through innovation and market expansion, but investors should monitor execution on strategic initiatives and margin sustainability amid economic uncertainties.

Twist Bioscience Corp

TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.

The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Msci Inc

MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.

Read more on MSCI

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST